Letter comments on a published article in the New England Journal of Medicine
- PMID: 30361101
- DOI: 10.1016/j.ejca.2018.09.020
Letter comments on a published article in the New England Journal of Medicine
Comment on
-
Brentuximab vedotin for frontline Hodgkin lymphoma: How much will a successful trial cost patients and payers?Eur J Cancer. 2018 Nov;104:252-253. doi: 10.1016/j.ejca.2018.09.021. Epub 2018 Oct 17. Eur J Cancer. 2018. PMID: 30342911 No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical